Furfuryl Acetate

• Free Radical Scavengers
• Antiparkinson Agents
• Antidyskinetics
• Antioxidants
• ATC:N04BC05

• Furfuryl Acetate
• Mirapex
• Pramipexole hydrochloride
• Pramipexol
• Pramipexol [Spanish]
• Pramipexole 2HCl Monohydrate
• Pramipexole [Usan:Inn]
• Pramipexolum [Latin]
• SUD919CL2Y

No information avaliable

C₁₀H₁₇N₃S

http://www.rxlist.com/cgi/generic2/prampex.htm

Aucune information disponible

211.324 g/mol

No information avaliable

Aucune information disponible

Solid

No information avaliable

Tablet

Pour le traitement des signes et des symptômes de la maladie de Parkinson idiopathique

Le pramipexole est un agoniste de la dopamine avec une relative haute nonergot dans la spécificité in vitro et une activité intrinsèque complète à la sous-famille des récepteurs de la dopamine D2, liant avec une affinité plus élevée à D3 que de D2 ou Types de récepteurs D4. La pertinence de la liaison du récepteur D3 dans la maladie de Parkinson n'est pas connue. Le mécanisme d'action précis du pramipexole dans le traitement de la maladie de Parkinson est inconnue, bien il est censé être lié à sa capacité à stimuler les récepteurs de dopamine dans le striatum. Cette conclusion est étayée par des études électrophysiologiques chez l'animal qui ont montré que le pramipexole influences striatale taux décharges neuronales via l'activation de récepteurs de dopamine dans le striatum et la substantia nigra, le site de neurones qui envoient des projections vers le striatum.

Aucune information disponible

Aucune information disponible

Patients should be instructed to take MIRAPEX only as prescribed.

Patients should be informed that hallucinations can occur and that the elderly are at a higher risk than younger patients with Parkinson 's disease.

Patients may develop postural (orthostatic) hypotension, with or without symptoms such as dizziness, nausea, fainting or blackouts, and sometimes, sweating. Hypotension may occur more frequently during initial therapy. Accordingly, patients should be cautioned against rising rapidly after sitting or lying down, especially if they have been doing so for prolonged periods and especially at the initiation of treatment with MIRAPEX.

Patients should be advised that MIRAPEX may cause somnolence and that they should neither drive a car nor operate other complex machinery until they have gained sufficient experience on MIRAPEX to gauge whether or not it affects their mental and/or motor performance adversely. Because of the possible additive sedative effects, caution should also be used when patients are taking other CNS depressants in combination with MIRAPEX.

Because the teratogenic, potential of pramipexole has not been completely established in laboratory animals, and because experience in humans is limited, patients should be advised to notify their physicians if they become pregnant or intend to become pregnant during therapy.

Because of the possibility that pramipexole may be excreted in breast milk, patients should be advised to notify their physicians if they intend to breast-feed or are breast-feeding an infant.

If patients develop nausea, they should be advised that taking MIRAPEX with food may reduce the occurrence of nausea.

Les humains et autres mammifères